                         SEQUENCE LISTING

<110>  Lancaster University Business Enterprises Limited 
       Holscher, Christian
 
<120>  Treatment of Neurological Diseases

<130>  P031098

<140>  GB1620611.2
<141>  2016-12-05

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  VARIANT
<222>  (2), (20)
<223>  Xaa = alpha amino-isobutyric acid

<220>
<221>  VARIANT
<222>  (24)
<223>  Xaa = Cys or Asn

<220>
<221>  VARIANT
<222>  (30)
<223>  Xaa = absent or an extension comprising at least eight amino acid
       molecules

<220>
<221>  VARIANT
<222>  (31)
<223>  Xaa = extension comprising Lys Lys Lys Lys Lys or Lys Lys Lys Lys
       Lys Lys or Arg Arg Gln Arg Arg Lys Lys Arg Gly Tyr  or Lys Arg 
       Arg Gln Arg Arg Lys Lys Arg Gly Tyr

<400>  1

Tyr Xaa Glu Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys 
1               5                   10                  15      


Gln Ala Ala Xaa Glu Phe Val Xaa Trp Leu Leu Ala Gly Xaa Xaa 
            20                  25                  30      


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  2

Lys Lys Lys Lys Lys 
1               5   


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  3

Lys Lys Lys Lys Lys Lys 
1               5       


<210>  4
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  4

Arg Arg Gln Arg Arg Lys Lys Arg Gly Tyr 
1               5                   10  


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  5

Lys Arg Arg Gln Arg Arg Lys Lys Arg Gly Tyr 
1               5                   10      


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  6

Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser 
1               5                   10  


<210>  7
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  7

Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser Lys 
1               5                   10      


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  8

Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser Cys 
1               5                   10      


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  9

Pro Ser Ser Gly Ala Pro Pro Pro Ser 
1               5                   


<210>  10
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  10

Pro Ser Ser Gly Ala Pro Pro Ser 
1               5               


<210>  11
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GIP/GLP-1 co-agonist peptide


<220>
<221>  VARIANT
<222>  (2), (20)
<223>  Xaa = alpha amino-isobutyric acid

<400>  11

Tyr Xaa Glu Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys 
1               5                   10                  15      


Gln Ala Ala Xaa Glu Phe Val Asn Trp Leu Leu Ala Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser Lys Lys Lys Lys Lys Lys 
        35                  40                  45  


<210>  12
<211>  50
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GIP/GLP-1 co-agonist peptide


<220>
<221>  VARIANT
<222>  (2), (20)
<223>  Xaa = alpha amino-isobutyric acid

<400>  12

Tyr Xaa Glu Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys 
1               5                   10                  15      


Gln Ala Ala Xaa Glu Phe Val Asn Trp Leu Leu Ala Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser Lys Arg Arg Gln Arg Arg Lys Lys Arg 
        35                  40                  45              


Gly Tyr 
    50  


<210>  13
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human Glucagon-like Peptide 1

<400>  13

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly 
            20                  25                  30      


<210>  14
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human Gastric inhibitory peptide (glucose-dependent 
       insulinotropic peptide)

<400>  14

Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys 
1               5                   10                  15      


Ile His Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys Gly Lys 
            20                  25                  30          


Lys Asn Asp Trp Lys His Asn Ile Thr Gln 
        35                  40          


<210>  15
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Liraglutide


<220>
<221>  VARIANT
<222>  (20)
<223>  Xaa = Lys residue comprising gamma-glutamate linker between C16 
       palmitoyl group and lysine side-chain amino group.

<400>  15

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Xaa Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 
            20                  25                  30      


<210>  16
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DAla2-GIP-Lys37- y-Glu-PA


<220>
<221>  VARIANT
<222>  (2)
<223>  Xaa = d-Ala

<220>
<221>  VARIANT
<222>  (33)
<223>  Xaa = Lys (y-E-C16)

<400>  16

Tyr Xaa Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys 
1               5                   10                  15      


Ile His Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys Gly Lys 
            20                  25                  30          


Xaa Asn Asp Trp Lys His Asn Ile Thr Gln 
        35                  40          


